A faster-acting injected mealtime insulin, Fiasp (“fast-acting insulin aspart”) is now FDA approved and expected to be available at the end of 2017 or early in 2018.
Fiasp is a new formulation of NovoLog, which includes the addition of niacinamide (vitamin B3) to increase the speed of the initial insulin absorption, resulting in an onset of appearance in the blood in approximately 2.5 minutes.
Fiasp is approved for adults with type 1 and type 2 diabetes and will launch at the same price as NovoLog. The newly-approved insulin has a faster onset and offset. On the front end, Fiasp starts working within minutes of injection and it can be taken as much as 20 minutes after starting a meal. While taking it at the beginning of the meal is strongly recommended, this dosing flexibility may be beneficial for some patients.
“The intention of rapid acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, a process that is important for optimal A1C management.” said Bruce Bode, MD FACE, President of Atlanta Diabetes Associates and Associate Professor at Emory University School of Medicine.
Fiasp will be packaged in Flex Touch Pens and 10mL vials.
September 5 – September 7
July 6 @ 11:30 am – 1:00 pm
July 9 @ 11:30 am – 12:45 pm
July 12 @ 11:30 am – 1:00 pm
July 18 @ 11:30 am – 12:40 pm
July 19 @ 11:30 am – 1:00 pm